126 related articles for article (PubMed ID: 38206735)
1. KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinoma.
Li N; Tian Y; Liu X; Pan C; Xue J
Medicine (Baltimore); 2023 Dec; 102(52):e36597. PubMed ID: 38206735
[TBL] [Abstract][Full Text] [Related]
2. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous
Meder L; Florin A; Ozretić L; Nill M; Koker M; Meemboor S; Radtke F; Diehl L; Ullrich RT; Odenthal M; Büttner R; Heukamp LC
Pathol Oncol Res; 2021; 27():596522. PubMed ID: 34257546
[No Abstract] [Full Text] [Related]
3. KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer.
Liang H; Zhou G; Lv L; Lu J; Peng J
Breast Cancer; 2021 Mar; 28(2):379-386. PubMed ID: 33067762
[TBL] [Abstract][Full Text] [Related]
4. YTHDF1 Promotes Cyclin B1 Translation through m
Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
[TBL] [Abstract][Full Text] [Related]
5. ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Bogucka K; Marini F; Rosigkeit S; Schloeder J; Jonuleit H; David K; Schlackow M; Rajalingam K
Cancer Gene Ther; 2021 May; 28(5):359-374. PubMed ID: 33070159
[TBL] [Abstract][Full Text] [Related]
6. REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
Sun S; Hu Z; Huang S; Ye X; Wang J; Chang J; Wu X; Wang Q; Zhang L; Hu X; Yu H
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2273-2283. PubMed ID: 31428934
[TBL] [Abstract][Full Text] [Related]
7. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
8. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
9.
Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
[No Abstract] [Full Text] [Related]
10. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
11. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma.
Villaruz LC; Socinski MA; Cunningham DE; Chiosea SI; Burns TF; Siegfried JM; Dacic S
Cancer; 2013 Jun; 119(12):2268-74. PubMed ID: 23526491
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
13. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
Dai D; Shi R; Han S; Jin H; Wang X
Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
[TBL] [Abstract][Full Text] [Related]
14. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
15. Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival.
Nikou S; Arbi M; Dimitrakopoulos FD; Sirinian C; Chadla P; Pappa I; Ntaliarda G; Stathopoulos GT; Papadaki H; Zolota V; Lygerou Z; Kalofonos HP; Bravou V
J Mol Histol; 2020 Aug; 51(4):385-400. PubMed ID: 32592097
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Data Analysis of Patients With Metastatic Lung Adenocarcinoma With or Without
Moeller M; Schaedlich F; Schuette W
Cancer Control; 2022; 29():10732748221126949. PubMed ID: 36355617
[TBL] [Abstract][Full Text] [Related]
17. Identification of LGR4 as a prognostic biomarker in KRAS-mutant lung adenocarcinoma: Evidence from integrated bioinformatics analysis.
Dodin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36084. PubMed ID: 37986325
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
19. The ERBB network facilitates KRAS-driven lung tumorigenesis.
Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
[TBL] [Abstract][Full Text] [Related]
20. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
Fan K; Zhang BH; Han D; Sun YC
BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
